Injeq raised 3 million euros in record time

Injeq launched a 3 million euros convertible bond on March 23rd to secure growth. Investors subscribed the loan at a record pace and the loan was fully subscribed a week later.

Injeq first offered an investment opportunity to the existing, approximately 1,200 shareholders, who subscribed the loan at a record pace. A day after the start of the financing round, the accumulated capital had risen to more than one and a half million euros. The public offering began on March 30th, and the loan was fully subscribed on the same day.

Despite the uncertainty caused by the war between Russia and Ukraine in the world economy, shareholders’ confidence in Injeq has remained strong. The impact of the Ukrainian crisis on Injeq’s business is small, at least for the time being. There is nothing related to Russia, Belarus or Ukraine in Injeq’s supply chain, and the company’s products are not sold in these countries.

Now, for the fourth time, the capital raised through Invesdor will be used to finance growth in line with the strategy; marketing, research and development and working capital security. In addition, the revenue stream is sought from the recently started sales. The IPO is still strongly in Injeq’s plans.

Further information

Injeq Oyj
Tommi Rasila, Chairman of the Board
tel. 040 750 8158
tommi.rasila@injeq.com

Injeq Oyj
Timo Hänninen, CEO
tel. 050 518 1830
timo.hanninen@injeq.com

 

Injeq in brief 

Injeq Oyj is a Finnish growth company in innovative medical technology, whose mission is to produce technically intelligent solutions for medically demanding patient injections. Developed at the request of physicians, the IQ-Tip® smart needle facilitates physicians’ work to improve patient safety and treatment effectiveness.

The IQ-Tip® smart needle is a modern way to perform demanding patient injections safely. The first stage is lumbar puncture, a clinical procedure in which the spinal fluid is sampled or a drug is administered into the spinal cavity. The clinical performance and safety of the product at lumbar punctures have been evaluated in three clinical trials in Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, one of the main uses being for the treatment of leukemia children.

Founded in 2010, Injeq operates in Tampere and currently employs 19 people. Injeq is supported by an experienced team of medical experts and extensive scientific research. IQ-Tip® is a registered trademark of Injeq.

Injeq webinar today, Thursday Feb 22nd, 2024

Welcome to the webinar “Innovation in lumbar punctures” on February 22nd, 2024, at 7:00 pm (Madrid time Zone)   Lecturers […]
Read more »

INJEQ IQ-Tip Webinar February 22nd, 2024

Join the webinar revealing the revolutionary technique of lumbar punctures for healthcare professionals. Discover the innovative technology behind Injeq IQ-Tip®, […]
Read more »

HKTDC London office is proud of INJEQ’s achievements

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong […]
Read more »

EGM March 1, 2024

NOTICE OF THE EXTRAORDINARY GENERAL MEETING KUTSU YLIMÄÄRÄISEEN YHTIÖKOKOUKSEEN Notice is given to the shareholders of Injeq Oyj of the […]
Read more »

Arab Health 2024 started – Injeq meets with customers

Arab Health 2024, the intersection of cutting-edge technologies, revolutionary concepts, and healthcare experts, is reshaping the healthcare landscape. Injeq CEO […]
Read more »

Season greetings!

Injeq kiittää kaikkia asiakkaitaan ja sidosryhmiään yhteistyöstä vuonna 2023 ja toivottaa rauhallista joulun aikaa! Onnea ja iloa uuteen vuoteen 2024! […]
Read more »